The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm, phase II trial to evaluate the efficacy and safety of
500mg Fulvestrant (Faslodex®) in ESR1 mutated postmenopausal women with hormone receptor
positive, HER2 negative locally advanced or metastatic breast cancer after previous aromatase
inhibitor therapy. Fifty patients will be enrolled and treated with 500 mg Fulvestrant until
disease progression or study closed.
Treatment will continue until disease progression, unless any of the criteria for treatment
discontinuation are met first. If a patient progresses during the treatment period, the
patient must be withdrawn from the treatment and further treatment will be at the
investigator's discretion.